Pfizer just had a big setback in its race for an Ozempic competitor
Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.Read more...
Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.
